244 related articles for article (PubMed ID: 21131319)
1. In vitro and in vivo prophylactic and curative activity of the triterpene saponin PX-6518 against cutaneous Leishmania species.
Inocêncio da Luz RA; Vermeersch M; Deschacht M; Hendrickx S; Van Assche T; Cos P; Maes L
J Antimicrob Chemother; 2011 Feb; 66(2):350-3. PubMed ID: 21131319
[TBL] [Abstract][Full Text] [Related]
2. Leishmanicidal activity of the Agaricus blazei Murill in different Leishmania species.
Valadares DG; Duarte MC; Oliveira JS; Chávez-Fumagalli MA; Martins VT; Costa LE; Leite JP; Santoro MM; Régis WC; Tavares CA; Coelho EA
Parasitol Int; 2011 Dec; 60(4):357-63. PubMed ID: 21723957
[TBL] [Abstract][Full Text] [Related]
3. Activity of pentostam (sodium stibogluconate) against cutaneous leishmaniasis in mice treated with neutralizing anti-interferon-gamma antibody.
Nabors GS; Farrell JP
Am J Trop Med Hyg; 1995 Jul; 53(1):55-60. PubMed ID: 7625533
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine mediated microbicidal activity of peritoneal macrophages from Leishmania donovani infected and drug treated BALB/c mice.
Sodhi S; Ganguly NK; Malla N; Mahajan RC
Jpn J Exp Med; 1989 Jun; 59(3):103-8. PubMed ID: 2554031
[TBL] [Abstract][Full Text] [Related]
5. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs.
Garnier T; Mäntylä A; Järvinen T; Lawrence J; Brown M; Croft S
J Antimicrob Chemother; 2007 Oct; 60(4):802-10. PubMed ID: 17715126
[TBL] [Abstract][Full Text] [Related]
6. Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines.
Daneshvar H; Coombs GH; Hagan P; Phillips RS
J Infect Dis; 2003 May; 187(10):1662-8. PubMed ID: 12721947
[TBL] [Abstract][Full Text] [Related]
7. The in vivo activity of 1,3,4-thiadiazolium-2-aminide compounds in the treatment of cutaneous and visceral leishmaniasis.
Rodrigues RF; Charret KS; Campos MC; Amaral V; Echevarria A; Dos Reis C; Canto-Cavalheiro MM; Leon LL
J Antimicrob Chemother; 2012 Jan; 67(1):182-90. PubMed ID: 21987238
[TBL] [Abstract][Full Text] [Related]
8. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
Rachamim N; Jaffe CL
J Immunol; 1993 Mar; 150(6):2322-31. PubMed ID: 8450215
[TBL] [Abstract][Full Text] [Related]
9. In vivo activity of perifosine against Leishmania amazonensis.
Cabrera-Serra MG; Valladares B; Piñero JE
Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328
[TBL] [Abstract][Full Text] [Related]
10. Leishmania major: activity of tamoxifen against experimental cutaneous leishmaniasis.
Eissa MM; Amer EI; El Sawy SM
Exp Parasitol; 2011 Aug; 128(4):382-90. PubMed ID: 21620834
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes.
Miguel DC; Yokoyama-Yasunaka JK; Andreoli WK; Mortara RA; Uliana SR
J Antimicrob Chemother; 2007 Sep; 60(3):526-34. PubMed ID: 17584801
[TBL] [Abstract][Full Text] [Related]
12. Effects of anti-Leishmania monoclonal antibodies on the development of Leishmania major in Phlebotomus duboscqi (Diptera: Psychodidae).
Anjili C; Langat B; Ngumbi P; Mbati PA; Githure J; Tonui WK
East Afr Med J; 2006 Feb; 83(2):72-8. PubMed ID: 16708877
[TBL] [Abstract][Full Text] [Related]
13. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani.
Carter KC; Mullen AB; Sundar S; Kenney RT
Antimicrob Agents Chemother; 2001 Dec; 45(12):3555-9. PubMed ID: 11709339
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
[TBL] [Abstract][Full Text] [Related]
15. The activity of nitrofurazone and furazolidone against Leishmania donovani, L. major and L. enriettii in vitro and in vivo.
Neal RA; van Bueren J; Hooper G
Ann Trop Med Parasitol; 1988 Oct; 82(5):453-6. PubMed ID: 2855778
[TBL] [Abstract][Full Text] [Related]
16. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
Tonui WK; Titus RG
Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
[TBL] [Abstract][Full Text] [Related]
17. Leishmania donovani: pilot study for evaluation of therapeutic effects of inosine analogs against amastigotes in vitro and in vivo.
Morishige K; Aji T; Ishii A; Yasuda T; Wataya Y
Exp Parasitol; 1995 Jun; 80(4):665-71. PubMed ID: 7758547
[TBL] [Abstract][Full Text] [Related]
18. Activity of physalins purified from Physalis angulata in in vitro and in vivo models of cutaneous leishmaniasis.
Guimarães ET; Lima MS; Santos LA; Ribeiro IM; Tomassini TB; Ribeiro dos Santos R; dos Santos WL; Soares MB
J Antimicrob Chemother; 2009 Jul; 64(1):84-7. PubMed ID: 19454526
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory effect of Canova medication on experimental Leishmania amazonensis infection.
Pereira WK; Lonardoni MV; Grespan R; Caparroz-Assef SM; Cuman RK; Bersani-Amado CA
J Infect; 2005 Aug; 51(2):157-64. PubMed ID: 16038768
[TBL] [Abstract][Full Text] [Related]
20. In vivo antileishmanial action of Ir-(COD)-pentamidine tetraphenylborate on Leishmania donovani and Leishmania major mouse models.
Loiseau PM; Mbongo N; Bories C; Boulard Y; Craciunescu DG
Parasite; 2000 Jun; 7(2):103-8. PubMed ID: 10887656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
